Elliott Sigal, M.D., Ph.D.

Director

Elliott Sigal, M.D., Ph.D., has served as a member of our Board since July 2020. 

Dr. Sigal currently serves as a senior advisor to select biotechnology companies. He is co-chair of the Scientific Advisory Board of Amgen, a member of the board of directors for the public biotechnology company Alnylam Pharmaceuticals, as well as the private companies Tessera Therapeutics and Affinia Therapeutics. 

Dr. Sigal is a former Executive Vice President and member of the board of directors of Bristol-Myers Squibb Company, and served as Chief Scientific Officer and President of R&D from 2004 until 2013. Under his leadership, 14 new medicines came to market. In addition, he previously served as a member of the boards of directors of several public life sciences companies, including Adaptimmune Therapeutics, Surface Oncology, Spark Therapeutics and Mead Johnson Nutrition. 

Positions prior to BMS include a faculty appointment at University of California, San Francisco (UCSF), senior executive roles at Syntex/Roche and CEO of the genomics firm, Mercator Genetics.

Dr. Sigal holds B.S., M.S. and Ph.D. degrees in industrial engineering from Purdue University and an M.D. from the University of Chicago.